title: The pharmacologic and clinical properties of Oxis (formoterol) Turbuhaler.
abstract: Oxis Turbuhaler has been approved for use in Europe at doses of 6, 12, or 24 micrograms once or twice daily. It has a rapid onset of action (within minutes) and demonstrates a maintained effect on airway function (an improvement of 20-30 l/min in PEF is seen 12 h after dosing), and it is well tolerated and safe. It decreases the incidence of acute asthma attacks, stimulates an immediate increase in PEF (in the order of 40-45 l/min), is effective when given in conjunction with anti-inflammatory medication, and has been shown to maintain a level of asthma control in all studies performed. Hence, Oxis Turbuhaler is a clinically relevant tool for use in patients receiving inhaled corticosteroids who require additional control of their asthma symptoms.
authors.affiliation: Department of Clinical Research, Lund, Sweden.
authors.forename: O
authors.initials: O
authors.lastname: Selroos
mesh_terms: D000280:Administration, Inhalation; D001249:Asthma / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000068759:Formoterol Fumarate; D006801:Humans
chemical_list: D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068759:Formoterol Fumarate